Analytical description of adverse events with long-acting injectable cabotegravir and rilpivirine in people living with HIV: a large multicentre prospective observational cohort study (SCOLTA).

Long-acting injectable cabotegravir plus rilpivirine (LA CAB+RPV) is a highly effective, well-tolerated antiretroviral regimen, but real-world adverse event (AE) data remain limited. We characterised the type and frequency of AEs associated with LA CAB+RPV in people with HIV in routine clinical prac